Amgen’s Sotorasib Updates Raise New Questions For KRAS Program
Lower Dose Being Tested Against Higher Dose Under FDA Review
The company provided updates on the timing of some data from its extensive clinical program for its KRAS G12C inhibitor Lumakras, but not for certain high-profile combinations.
You may also be interested in...
Scrip discussed key wins for sotorasib in lung cancer and tezepelumab in asthma with Amgen executives Murdo Gordon and David Reese, but COVID-19 and other challenges are looming.
Results from the Phase II CodeBreak 100 study of sotorasib presented at the World Conference on Lung Cancer were included in Amgen’s applications for approvals in the US, EU and other countries.
Tucatinib, approved for advanced unresectable or metastatic HER2-positive breast cancer, has a list price of $18,500 per month or $111,000 for a full course. Doctors can order the drug immediately.